Jennison Associates’s Cytokinetics CYTK Stock Holding History

Jennison Associates’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-673,932	Closed	-$27.1M	–	597
2025 Q1	$27.1M	Buy	+673,932	New	+$31M	0.02%	295
2022 Q4	–	Sell	-14,358	Closed	-$696K	–	586
2022 Q3	$696K	Buy	+14,358	New	+$691K	﹤0.01%	549
2020 Q4	–	Sell	-270,382	Closed	-$5.85M	–	661
2020 Q3	$5.85M	Sell	270,382 -346,801	-56%	-$8.11M	﹤0.01%	423
2020 Q2	$14.5M	Buy	617,183 +3,029	+0.5%	+$56.8K	0.01%	328
2020 Q1	$7.24M	Buy	614,154 +4,190	+0.7%	+$53.5K	0.01%	368
2019 Q4	$6.47M	Buy	+609,964	New	+$6.27M	0.01%	414
2014 Q2	–	Sell	-250,000	Closed	-$2.38M	–	721
2014 Q1	$2.38M	Buy	+250,000	New	+$2.26M	﹤0.01%	572

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Jennison Associates's CYTK Position: Q2 2025 in Review

Jennison Associates sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 673,932 shares — an estimated $27.1M sold.

Jennison Associates first reported a position in CYTK in Q1 2014 and held it in 7 quarters. The position peaked at $27.1M in Q1 2025. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

Jennison Associates reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
Jennison Associates sold 673,932 Cytokinetics shares in Q2 2025, an estimated $27.1M.
Jennison Associates first reported a position in Cytokinetics in Q1 2014 and held it in 7 quarters.
Jennison Associates's Cytokinetics position peaked at $27.1M in Q1 2025.
311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on Jennison Associates's 13F filing for Q2 2025, filed 1 Aug 2025.